Bryan Garnier - ABIVAX (ABVX) Abivax: reports FY 2023 and reiterates timelines

Report

Bryan Garnier

Oscar Haffen Lamm

Abivax: reports FY 2023 and reiterates timelines

Abivax reported its FY 2023 financial results, which highlighted the total EUR 500m raised in 2023 (incl. EUR 130m capital increase, two structured debt financing transactions aggregating EUR 150m and EUR 223.3m US IPO). In particular, the financial results highlighted i) operating loss at EUR -127

02/04/2024 1 EN

Underlying

ABIVAX

See profile

US00370M1036 Non National NASDAQ Stock Exchange France

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Oscar Haffen Lamm

Other Reports on these Companies

Bryan Garnier

H1 2024 results in-line with expectations

Abivax today reported H12024 results reporting a cash balance at EUR 222.3mn and a cash reach to Q4 2025, thereby reiterating preliminary figures provided last July. The EUR 85.2mn cash used in operation was principally driven by increased R&D spending (EUR 64.7mn) on the Phase III in UC (ABTEC

September 10, 2024 September 10, 2024 1 EN

Bryan Garnier

Abivax: ABTECT study enrollment on track

Abivax today provided an update on the enrollment status into its ABTECT phase III study, disclosing the enrollment of the 600th patient and confirms enrollment completion for Q1 2025 (read-out for Q2 2025).Good to know, Abivax confirmed that to date, baseline participants baseline characteristics

August 6, 2024 August 6, 2024 1 EN

Bryan Garnier

Abivax minor Ph. III read-out delay

Yesterday after close, Abivax provided an update on the enrollment status into its ABTECT phase III study, disclosing a single quarter delay in the expected read-out, now scheduled for Q2 2025. Considering the complexity of the study (600 sites, 1,200 patients) we do not see any red flags in such m

July 16, 2024 July 16, 2024 1 EN

BICO: CMD takeaways, a new vision amid tough market

Yesterday, BICO held a Capital Markets Day (CMD) where the new top executive management team provided an in-depth view of the renewed BICO 2.0 strategy. Aware of the Life Science (LS) Tools and Bioconvergence post-pandemic tough market conditions, the company's new vision focuses on Lab Automation

September 20, 2024 September 20, 2024 1 EN

Maria Vara

Maria Vara

XVIVO: acquisition of an innovative communication platform to save more lives

XVIVO is expanding its service offering with the acquisition of the FlowHawk software platform from OmniLife, aiming to streamline the complex planning and communication involved in organ transplantation, ensuring that "no one should die waiting for a new organ." The FlowHawk platform has proven it

September 20, 2024 September 20, 2024 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Carbios: partnership with Sleever

Yesterday, Carbios announced it had signed an agreement with Sleever, a French leader in shrinksleeve label technology, for an exclusive, long-term contract to jointly develop biodegradable shrink films. This signature confirms Carbios' leadership in enzyme engineering and interest from partners in

September 20, 2024 September 20, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Abivax: reports FY 2023 and reiterates timelines

H1 2024 results in-line with expectations

Abivax: ABTECT study enrollment on track

Abivax minor Ph. III read-out delay

BICO: CMD takeaways, a new vision amid tough market

XVIVO: acquisition of an innovative communication platform to save more lives

Carbios: partnership with Sleever

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe